Morningstar

OrganiGram Holdings Inc OGI

Morningstar Rating

Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment

Business Wire Sep 3, 2024 10:00am
Cannabis stocks drop sharply as DEA sets drug-rescheduling hearing after November election

MarketWatch Aug 27, 2024 4:43pm
OrganiGram's stock rises as Canadian pot company's revenue tops analyst estimate

MarketWatch Aug 13, 2024 6:16pm
Organigram Reports Third Quarter Fiscal 2024 Results

Business Wire Aug 13, 2024 10:30am
Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology

Business Wire Aug 7, 2024 10:00am
Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024

Business Wire Aug 6, 2024 10:00am
How the head of cannabis company Cronos dealt with a negative report from indicted short seller Andrew Left

MarketWatch Aug 2, 2024 3:16pm
Organigram Announces Appointment of Craig Harris to Board of Directors

Business Wire Jul 29, 2024 10:00am
Organigram to Bolster Auto-Flower and Rare Cannabinoid Portfolio with Partial Third Tranche Investment of US $1M into Phylos

Business Wire Jul 24, 2024 10:00am
Toronto Stocks Edge Down; Hudbay Minerals Rises on 1Q Earnings Beat

Global News Select May 14, 2024 4:13pm
Nasdaq finally 'warming up' to Canadian cannabis companies with U.S. exposure. Could American growers be next?

MarketWatch May 3, 2024 8:45pm
Organigram Shares Rise 29% After Investment By BAT Subsidiary

Global News Select Nov 6, 2023 3:25pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.